Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients
As a rare complication of mitoxantrone (MITOX) therapy in multiple sclerosis (MS), a therapy-related acute leukaemia (TRAL) may develop. The incidence is difficult to estimate, as frequently single cases are reported, up to now a total of eight MS patients. Here we report a new case out of 644 patie...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2004-08, Vol.10 (4), p.472-474 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 474 |
|---|---|
| container_issue | 4 |
| container_start_page | 472 |
| container_title | Multiple sclerosis |
| container_volume | 10 |
| creator | Voltz, Raymond Starck, Michaela Zingler, Vera Strupp, Michael Kolb, Hans-Jochem |
| description | As a rare complication of mitoxantrone (MITOX) therapy in multiple sclerosis (MS), a therapy-related acute leukaemia (TRAL) may develop. The incidence is difficult to estimate, as frequently single cases are reported, up to now a total of eight MS patients. Here we report a new case out of 644 patients. This is a 45-year-old female patient with secondary progressive MS who developed TRAL after a total dose of 48 mg/m2 MITOX. The TRAL was classified as acute myeloblastic leukaemia (AML) M4eo and showed an inversion of chromosome 16 and a partial trisomy 11. Her TRAL was treated with chemotherapy followed by allogeneic bone marrow transplantation. It responded well to the transplantation, whereas the MS symptoms initially worsened but have nearly returned to the pretransplantation level. This report brings the currently published frequency of MITOX-associated TRAL in MS therapy to five in a total of 2336 treated MS patients, representing an incidence of 0.21%. |
| doi_str_mv | 10.1191/1352458504ms1047cr |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17821661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1191_1352458504ms1047cr</sage_id><sourcerecordid>17821661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-f9dfaaeb55f96c4082d8e41904088ea7794ade8e31c79289b7c7968dd6c6d7023</originalsourceid><addsrcrecordid>eNp90U1LHjEQAOAgLfWrf8CDhEK9bU2yySbpTaRqQfGi52XeZFaj-2WSBf33Rt4XFAs9hJnDM5NhhpADzn5xbvkxr5WQyigmh8SZ1C5ukR0uta6Y1exLyQuo3sQ22U3pgTGmda2-kW2uaqGZtDskXIU8PcOY4zQizfcYYX6hYaTD0ucw90iT6zFOKSQKo6fgloy0x-URcAjwmwJ1kJBGnKeY6bSU19FGSpojQkZPZ8gBx5z2ydcO-oTfN3GP3J79uTm9qC6vz_-enlxWTqomV531HQCulOps4yQzwhuU3LKSGgStrQSPBmvutBXGrnSJjfG-cY3XTNR75Gjdd47T04Ipt0NIDvseRpyW1HJtBG8aXuCPT_BhWuJYZmsFN0aoWuqCxBq5soMUsWvnGAaILy1n7dsV2n-vUIoON52X1YD-vWSz9gJ-bgAkB30XYXQhfXDWMGZVccdrl-AO38f7z9evNrGeyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218825347</pqid></control><display><type>article</type><title>Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Voltz, Raymond ; Starck, Michaela ; Zingler, Vera ; Strupp, Michael ; Kolb, Hans-Jochem</creator><creatorcontrib>Voltz, Raymond ; Starck, Michaela ; Zingler, Vera ; Strupp, Michael ; Kolb, Hans-Jochem</creatorcontrib><description>As a rare complication of mitoxantrone (MITOX) therapy in multiple sclerosis (MS), a therapy-related acute leukaemia (TRAL) may develop. The incidence is difficult to estimate, as frequently single cases are reported, up to now a total of eight MS patients. Here we report a new case out of 644 patients. This is a 45-year-old female patient with secondary progressive MS who developed TRAL after a total dose of 48 mg/m2 MITOX. The TRAL was classified as acute myeloblastic leukaemia (AML) M4eo and showed an inversion of chromosome 16 and a partial trisomy 11. Her TRAL was treated with chemotherapy followed by allogeneic bone marrow transplantation. It responded well to the transplantation, whereas the MS symptoms initially worsened but have nearly returned to the pretransplantation level. This report brings the currently published frequency of MITOX-associated TRAL in MS therapy to five in a total of 2336 treated MS patients, representing an incidence of 0.21%.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1191/1352458504ms1047cr</identifier><identifier>PMID: 15327049</identifier><identifier>CODEN: MUSCFZ</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Bone Marrow Transplantation ; Chromosome Inversion ; Chromosomes, Human, Pair 11 ; Chromosomes, Human, Pair 16 - genetics ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Female ; Humans ; Immunomodulators ; Leukemia, Myeloid, Acute - chemically induced ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - surgery ; Medical sciences ; Middle Aged ; Mitoxantrone - adverse effects ; Mitoxantrone - therapeutic use ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multiple Sclerosis, Chronic Progressive - drug therapy ; Multiple Sclerosis, Chronic Progressive - physiopathology ; Neurology ; Pharmacology. Drug treatments ; Severity of Illness Index ; Topoisomerase I Inhibitors ; Transplantation, Homologous ; Trisomy</subject><ispartof>Multiple sclerosis, 2004-08, Vol.10 (4), p.472-474</ispartof><rights>2004 INIST-CNRS</rights><rights>2004 Arnold</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-f9dfaaeb55f96c4082d8e41904088ea7794ade8e31c79289b7c7968dd6c6d7023</citedby><cites>FETCH-LOGICAL-c456t-f9dfaaeb55f96c4082d8e41904088ea7794ade8e31c79289b7c7968dd6c6d7023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1191/1352458504ms1047cr$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1191/1352458504ms1047cr$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15980095$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15327049$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Voltz, Raymond</creatorcontrib><creatorcontrib>Starck, Michaela</creatorcontrib><creatorcontrib>Zingler, Vera</creatorcontrib><creatorcontrib>Strupp, Michael</creatorcontrib><creatorcontrib>Kolb, Hans-Jochem</creatorcontrib><title>Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>As a rare complication of mitoxantrone (MITOX) therapy in multiple sclerosis (MS), a therapy-related acute leukaemia (TRAL) may develop. The incidence is difficult to estimate, as frequently single cases are reported, up to now a total of eight MS patients. Here we report a new case out of 644 patients. This is a 45-year-old female patient with secondary progressive MS who developed TRAL after a total dose of 48 mg/m2 MITOX. The TRAL was classified as acute myeloblastic leukaemia (AML) M4eo and showed an inversion of chromosome 16 and a partial trisomy 11. Her TRAL was treated with chemotherapy followed by allogeneic bone marrow transplantation. It responded well to the transplantation, whereas the MS symptoms initially worsened but have nearly returned to the pretransplantation level. This report brings the currently published frequency of MITOX-associated TRAL in MS therapy to five in a total of 2336 treated MS patients, representing an incidence of 0.21%.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Transplantation</subject><subject>Chromosome Inversion</subject><subject>Chromosomes, Human, Pair 11</subject><subject>Chromosomes, Human, Pair 16 - genetics</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Female</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Leukemia, Myeloid, Acute - chemically induced</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - surgery</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mitoxantrone - adverse effects</subject><subject>Mitoxantrone - therapeutic use</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multiple Sclerosis, Chronic Progressive - drug therapy</subject><subject>Multiple Sclerosis, Chronic Progressive - physiopathology</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><subject>Severity of Illness Index</subject><subject>Topoisomerase I Inhibitors</subject><subject>Transplantation, Homologous</subject><subject>Trisomy</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp90U1LHjEQAOAgLfWrf8CDhEK9bU2yySbpTaRqQfGi52XeZFaj-2WSBf33Rt4XFAs9hJnDM5NhhpADzn5xbvkxr5WQyigmh8SZ1C5ukR0uta6Y1exLyQuo3sQ22U3pgTGmda2-kW2uaqGZtDskXIU8PcOY4zQizfcYYX6hYaTD0ucw90iT6zFOKSQKo6fgloy0x-URcAjwmwJ1kJBGnKeY6bSU19FGSpojQkZPZ8gBx5z2ydcO-oTfN3GP3J79uTm9qC6vz_-enlxWTqomV531HQCulOps4yQzwhuU3LKSGgStrQSPBmvutBXGrnSJjfG-cY3XTNR75Gjdd47T04Ipt0NIDvseRpyW1HJtBG8aXuCPT_BhWuJYZmsFN0aoWuqCxBq5soMUsWvnGAaILy1n7dsV2n-vUIoON52X1YD-vWSz9gJ-bgAkB30XYXQhfXDWMGZVccdrl-AO38f7z9evNrGeyQ</recordid><startdate>200408</startdate><enddate>200408</enddate><creator>Voltz, Raymond</creator><creator>Starck, Michaela</creator><creator>Zingler, Vera</creator><creator>Strupp, Michael</creator><creator>Kolb, Hans-Jochem</creator><general>SAGE Publications</general><general>Arnold</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200408</creationdate><title>Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients</title><author>Voltz, Raymond ; Starck, Michaela ; Zingler, Vera ; Strupp, Michael ; Kolb, Hans-Jochem</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-f9dfaaeb55f96c4082d8e41904088ea7794ade8e31c79289b7c7968dd6c6d7023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Transplantation</topic><topic>Chromosome Inversion</topic><topic>Chromosomes, Human, Pair 11</topic><topic>Chromosomes, Human, Pair 16 - genetics</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Female</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Leukemia, Myeloid, Acute - chemically induced</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - surgery</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mitoxantrone - adverse effects</topic><topic>Mitoxantrone - therapeutic use</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multiple Sclerosis, Chronic Progressive - drug therapy</topic><topic>Multiple Sclerosis, Chronic Progressive - physiopathology</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><topic>Severity of Illness Index</topic><topic>Topoisomerase I Inhibitors</topic><topic>Transplantation, Homologous</topic><topic>Trisomy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Voltz, Raymond</creatorcontrib><creatorcontrib>Starck, Michaela</creatorcontrib><creatorcontrib>Zingler, Vera</creatorcontrib><creatorcontrib>Strupp, Michael</creatorcontrib><creatorcontrib>Kolb, Hans-Jochem</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Voltz, Raymond</au><au>Starck, Michaela</au><au>Zingler, Vera</au><au>Strupp, Michael</au><au>Kolb, Hans-Jochem</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2004-08</date><risdate>2004</risdate><volume>10</volume><issue>4</issue><spage>472</spage><epage>474</epage><pages>472-474</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><coden>MUSCFZ</coden><abstract>As a rare complication of mitoxantrone (MITOX) therapy in multiple sclerosis (MS), a therapy-related acute leukaemia (TRAL) may develop. The incidence is difficult to estimate, as frequently single cases are reported, up to now a total of eight MS patients. Here we report a new case out of 644 patients. This is a 45-year-old female patient with secondary progressive MS who developed TRAL after a total dose of 48 mg/m2 MITOX. The TRAL was classified as acute myeloblastic leukaemia (AML) M4eo and showed an inversion of chromosome 16 and a partial trisomy 11. Her TRAL was treated with chemotherapy followed by allogeneic bone marrow transplantation. It responded well to the transplantation, whereas the MS symptoms initially worsened but have nearly returned to the pretransplantation level. This report brings the currently published frequency of MITOX-associated TRAL in MS therapy to five in a total of 2336 treated MS patients, representing an incidence of 0.21%.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>15327049</pmid><doi>10.1191/1352458504ms1047cr</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2004-08, Vol.10 (4), p.472-474 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17821661 |
| source | MEDLINE; SAGE Complete |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone Marrow Transplantation Chromosome Inversion Chromosomes, Human, Pair 11 Chromosomes, Human, Pair 16 - genetics Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Female Humans Immunomodulators Leukemia, Myeloid, Acute - chemically induced Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - surgery Medical sciences Middle Aged Mitoxantrone - adverse effects Mitoxantrone - therapeutic use Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Chronic Progressive - physiopathology Neurology Pharmacology. Drug treatments Severity of Illness Index Topoisomerase I Inhibitors Transplantation, Homologous Trisomy |
| title | Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T02%3A07%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mitoxantrone%20therapy%20in%20multiple%20sclerosis%20and%20acute%20leukaemia:%20a%20case%20report%20out%20of%20644%20treated%20patients&rft.jtitle=Multiple%20sclerosis&rft.au=Voltz,%20Raymond&rft.date=2004-08&rft.volume=10&rft.issue=4&rft.spage=472&rft.epage=474&rft.pages=472-474&rft.issn=1352-4585&rft.eissn=1477-0970&rft.coden=MUSCFZ&rft_id=info:doi/10.1191/1352458504ms1047cr&rft_dat=%3Cproquest_cross%3E17821661%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218825347&rft_id=info:pmid/15327049&rft_sage_id=10.1191_1352458504ms1047cr&rfr_iscdi=true |